Home
This site is intended for healthcare professionals
Sign upLog in

Key Clinical Summary: Implementing Evidence‑Based CKD Screening Protocols for Patients With T2D

This is a micro-learning module summary of the session by Dr. Leigh Perreault which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent educational grant from Novo Nordisk. This education program is only available to healthcare professionals in the USA.

Introduction

This summary explores contemporary strategies for early detection of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D), outlining screening protocols, the clinical utility of urinary albumin‑to‑creatinine ratio (UACR) testing, and the integration of risk‑stratified monitoring into routine care. It reviews the interpretation of KDIGO risk categories and the importance of timely intervention to prevent both renal and cardiovascular complications.

Case‑Based Foundations for CKD Screening

  • A representative patient scenario illustrates common challenges in routine diabetes care: 58-year-old man, long T2D disease duration, inconsistent engagement, and incomplete risk assessment.
  • Key clinical features included BMI 34 kg/m2, BP 145/92 mmHg, A1c 8.5%, LDL 95 mg/dL, and eGFR 55 mL/min/1.73 m².
  • Despite multiple risk factors, a critical data point was missing: the UACR, which provides essential information about kidney damage.
  • Determining what to address first requires shared decision‑making, aligning clinical priorities with patient motivation and readiness for change.
  • The case underscores the need for systematic workflows that ensure UACR testing is incorporated into routine diabetes visits.

Role of UACR and eGFR in Risk Stratification

  • UACR reflects kidney damage, often preceding measurable declines in kidney function.
  • eGFR reflects kidney function, analogous to the percentage of renal ‘motor’ capacity remaining.
  • KDIGO’s heat map combines UACR and eGFR categories to stratify risk for CKD progression.
  • Higher UACR categories (≥30 mg/g and especially ≥300 mg/g) markedly increase risk, even when eGFR is relatively preserved.
  • The same risk grid predicts not only renal outcomes but also cardiovascular events, including myocardial infarction, stroke, heart failure, atrial fibrillation, and all‑cause mortality.
  • Communicating these risks helps patients understand why UACR testing is essential and how results guide treatment decisions.

Determining Screening Frequency

  • Screening intervals depend on the combination of eGFR and UACR:
    • UACR <30 mg/g: annual monitoring
    • UACR 30–300 mg/g: twice‑yearly monitoring
    • UACR >300 mg/g: three times per year
  • Increased frequency reflects higher risk of progression and the need for closer therapeutic adjustment.
  • Persistent abnormalities rather than single elevated values define CKD, making repeat testing essential.

Integrating UACR Testing Into Routine Care

  • Effective integration requires a multi‑layered approach:

    • Educating patients on the meaning and implications of UACR results
    • Ensuring clinicians understand how UACR informs risk stratification and treatment selection
    • Training staff to incorporate UACR testing into standard workflows
    • Using electronic medical record prompts, order sets, and reminders to prevent missed opportunities

  • Screening should begin:

    • 5 years after diagnosis for individuals with type 1 diabetes
    • At diagnosis for individuals with T2D, given the likelihood of delayed detection

Therapeutic Implications of Abnormal UACR

  • Treatment focuses on addressing the drivers of CKD progression—the ‘ABCs’ of diabetes care:
    • A1c: optimizing glycemic control
    • Blood pressure: prioritizing RAS blockade with ACE inhibitors or ARBs
    • Cholesterol: initiating or intensifying statin therapy
  • Foundational lifestyle interventions remain essential: nutrition, physical activity, smoking cessation, and weight management.
  • Pharmacologic therapy follows a structured hierarchy:
    • Metformin remains first‑line for glycemic control
    • SGLT2 inhibitors are recommended for all patients with T2D and CKD, independent of A1c, due to strong evidence for slowing CKD progression and reducing cardiovascular events
    • GLP‑1 receptor agonists also reduce CKD progression and cardiovascular risk and are expected to move toward earlier use in treatment algorithms
    • Additional agents with cardiorenal benefits include non‑steroidal mineralocorticoid receptor antagonists and antiplatelet therapies when indicated
  • Meta‑analyses demonstrate that SGLT2 inhibitors can reduce CKD progression by nearly 50%, extending time to end‑stage renal disease by more than a decade in some cases.
  • GLP‑1 receptor agonists provide complementary benefits, potentially through effects on proximal tubular sodium‑hydrogen exchange.

When to Refer to Nephrology

  • Referral is recommended for:
    • Persistent UACR >700 mg/g
    • UACR >300 mg/g accompanied by hematuria
    • A doubling of UACR in individuals with established albuminuria
  • These thresholds help standardize referral practices and ensure timely specialist involvement.

Conclusions

Early detection of CKD in individuals with T2D requires systematic, evidence‑based screening protocols that incorporate both UACR and eGFR. UACR is a sensitive marker of kidney damage and a powerful predictor of renal and cardiovascular outcomes, making it indispensable in routine diabetes care. Risk‑stratified monitoring, patient‑centred decision‑making, and timely initiation of therapies with proven cardiorenal benefits – particularly SGLT2 inhibitors and GLP‑1 receptor agonists – are essential to slowing disease progression. Clear referral criteria and well‑designed clinical workflows further support early intervention, ultimately improving long‑term outcomes for people with T2D.